Q-omics provides the consensus-scored CAPN3 profile across patient tissues and cancer cell-line models. CAPN3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CAPN3 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, CAPN3 protein abundance shows 21,272 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, LUAD, and HNSC as cancer lineages where CAPN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAPN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAPN3 survival associations across molecular data types. CAPN3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAPN3 RNA expression–survival associations across cancer types. High CAPN3 expression shows unfavorable associations in KIRC and COAD, but favorable associations in LIHC, LUAD, ACC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CAPN3 RNA expression.
This table summarizes CAPN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CAPN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAPN3 shows lower tumor expression in LUAD, KICH, HNSC, LUSC and KIRP and higher tumor expression in THCA. The LUAD box plot shows higher CAPN3 RNA expression in normal versus tumor tissue (log2 FC = −1.276, t-test p < 0.001).
This table shows molecular features associated with CAPN3 in patient tissues and cancer cell lines. In patient samples, CAPN3 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, CAPN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SKIN.
